Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

Overview

The investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary angioedema. The investigators believe that self administration with Icatibant for treatment of an acute attack of angioedema will not change the time to complete or near complete resolution of symptoms compared to treatment with Icatibant in a medical facility.

Full Title of Study: “Open Label, Multicenter Study to Evaluate Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema (IHA)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2014

Interventions

  • Drug: Icatibant
    • 30 mg subcutaneous dose of Icatibant

Arms, Groups and Cohorts

  • Experimental: Icatibant
    • Open-label study

Clinical Trial Outcome Measures

Primary Measures

  • Time to Complete or Near Complete Resolution From Onset of Symptoms
    • Time Frame: Time to complete or near complete resolution of symptoms as reported by the patient, an expected average of 8-10 hours
    • Time of onset of HAE attack, time icatibant was administered, and time to complete relief of symptoms were recorded in minutes. Time to complete relief of symptoms was defined as time from onset of symptoms to complete or near complete resolution as reported by the patient.

Secondary Measures

  • Percent Change in VAS Scores
    • Time Frame: Percent Change in VAS Score from Baseline to 4 Hours
    • Baseline, 4 hours VAS scale ranges from 0-100 with 0 being the lowest severity and 100 being the highest severity

Participating in This Clinical Trial

Inclusion Criteria

1. Males and females at least 18 years of age at the time of informed consent

2. Documented diagnosis of hereditary angioedema Type I or II based on ALL of the following criteria:

  • Family and/or medical history
  • Characteristic attack manifestations, recurrent attacks
  • Historical low C4, normal C1q and either low C1-INH or low C1INH function

3. Women of childbearing potential must use consistently and correctly a highly effective, adequate method of birth control (failure rate less than 1% per year), sexual abstinence or have a vasectomised partner during the duration of the study. Hormonal contraception can be continued if verified by a physician that it doesn't affect the course of hereditary angioedema attacks.

4. Mental and physical condition allowing patients to complete baseline assessment, to self-administer Icatibant and to follow other study procedures.

5. Ability to provide signed written informed consent after all aspects of the study have been explained and discussed with the patient.

Exclusion Criteria

1. Participation in a clinical therapeutic trial of another investigational medicinal product within the past month (except a previous Icatibant study).

2. Diagnosis of angioedema other than Type I or Type II hereditary angioedema.

3. Evidence of symptomatic coronary artery disease based on medical history, in particular, unstable angina pectoris or severe coronary heart disease.

4. Congestive heart failure (NYHA Class 3 and 4).

5. Stroke within the past 6 months.

6. Treatment with angiotensin converting enzyme inhibitor.

7. Pregnancy and/or breast-feeding.

8. In the opinion of the investigator: mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study.

9. In the opinion of the investigator: unlikely to comply with the protocol, for example, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study for any reason.

10. In the opinion of the investigator: inability to complete the patient diary, manage study medication or self-administration of an injection.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Massachusetts General Hospital
  • Collaborator
    • Shire Human Genetic Therapies, Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Aleena Banerji, MD, Assistant Professor of Medicine – Massachusetts General Hospital
  • Overall Official(s)
    • Aleena Banerji, M.D., Principal Investigator, Massachusetts General Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.